Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics. Antibody-drug conjugate specialist TORL ...

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago.

SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Thursday reported a loss of $116.2 million in its first quarter. On a per-share basis, the San Carlos ...

Iovance Biotherapeutics IOVA is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the ...

Iovance Biotherapeutics (NASDAQ: IOVA) didn't quite end the stock trading week on a high note. The company's shares were dinged by almost 6% that day, due largely to an analyst's recommendation ...

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated ...

Analysts' ratings for Iovance Biotherapeutics IOVA over the last quarter vary from bullish to bearish, as provided by 9 analysts. The table below provides a concise overview of recent ratings by ...

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy.